Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Phase-3 randomized trial of ev...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)
Bibliographic Details
Main Authors:
Chambers, J
,
Reed, N
,
Mansoor, W
,
Ross, P
,
Grossman, A
Format:
Conference item
Published:
2010
Holdings
Description
Similar Items
Staff View
Similar Items
Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
by: Gueorguiev, M, et al.
Published: (2010)
Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
by: Druce, MR, et al.
Published: (2009)
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
by: Fazio, N, et al.
Published: (2013)
Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2
by: Fazio, N, et al.
Published: (2011)
The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
by: Grozinsky-Glasberg, S, et al.
Published: (2009)